Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We previously reported 3-year outcomes of a single-arm prospective multicenter trial (AbiRT trial) of 33 patients with unfavorable intermediate risk (UIR) and favorable high risk (FHR) prostate cancer undergoing short course, combination therapy with ADT, AAP, and RT. Here we report the final analysis demonstrating a high rate of testosterone recovery (97%) and excellent biochemical progression-free survival (97%) at 5 years. These data support comparative prospective studies of shorter, more potent ADT courses in favorable high-risk prostate cancer.
Prostate cancer and prostatic diseases. 2024 Feb 22 [Epub ahead of print]
Ryan E Fecteau, Bridget F Koontz, Karen E Hoffman, Susan Halabi, Lauren E Howard, Monika Anand, Daniel J George, Tian Zhang, William R Berry, W Robert Lee, Michael R Harrison, Paul G Corn, Andrew J Armstrong
Department of Radiation Oncology, Duke University, Durham, NC, USA., East Carolina University Brody School of Medicine, Greenville, NC, USA., Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA., Department of Internal Medicine, Division of Hematology/Oncology, UT Southwestern Medical Center, Dallas, TX, USA., Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA. .